Is Geron Corp. (NASDAQ: GERN) Back In The Buying Zone?

Currently, there are 544.91M common shares owned by the public and among those 447.58M shares have been available to trade.

The company’s stock has a 5-day price change of -4.23% and 45.41% over the past three months. GERN shares are trading 50.24% year to date (YTD), with the 12-month market performance up to 46.08% higher. It has a 12-month low price of $1.64 and touched a high of $3.73 over the same period. GERN has an average intraday trading volume of 11.21 million shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by 18.07%, 39.25%, and 34.36% respectively.

Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.

Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!

Get the FREE Report with all the details here.


Institutional ownership of Geron Corp. (NASDAQ: GERN) shares accounts for 55.15% of the company’s 544.91M shares outstanding.

It has a market capitalization of $1.73B and a beta (3y monthly) value of 0.62. The earnings-per-share (ttm) stands at -$0.32. Price movements for the stock have been influenced by the stock’s volatility, which stands at 4.19% over the week and 9.99% over the month.

Analysts forecast that Geron Corp. (GERN) will achieve an EPS of -$0.1 for the current quarter, -$0.11 for the next quarter and -$0.17 for 2025. The lowest estimate earnings-per-share for the quarter is -$0.1 while analysts give the company a high EPS estimate of -$0.09. Comparatively, EPS for the current quarter was -$0.07 a year ago. Earnings per share for the fiscal year are expected to decrease by -1.56%, and 63.59% over the next financial year. EPS should grow at an annualized rate of 5.00% over the next five years, compared to -16.08% over the past 5-year period.

Looking at the support for the GERN, a number of firms have released research notes about the stock. Needham stated their Buy rating for the stock in a research note on March 15, 2024, with the firm’s price target at $4-$5. Goldman coverage for the Geron Corp. (GERN) stock in a research note released on September 12, 2023 offered a Buy rating with a price target of $4. Goldman was of a view on March 28, 2023 that the stock is Neutral, while Wedbush gave the stock Outperform rating on October 28, 2022, issuing a price target of $5. B. Riley Securities on their part issued Buy rating on July 28, 2022.

Most Popular

Related Posts